Pixantrone, a novel aza-anthracenedione with cytotoxic activity, was tested against the PPTP in vitro panel (3.0nM to 30.0μM) and against a limited panel of PPTP Wilms tumors and sarcomas (7.5mg/kg) administered intravenously using an every 4 day×3 schedule. In vitro pixantrone showed a median relative IC50 value of 54nM (range <3nM to 1.03μM). In vivo pixantrone induced significant differences in EFS distribution compared to controls in two of eight solid tumor xenografts at dose levels relevant to human drug exposure. A complete response was observed for one Wilms tumor xenograft. Pediatr Blood Cancer 2014;61:922-924.
- Developmental therapeutics
- Preclinical testing
- Topoisomerase 2 inhibitor
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health